AR065802A1 - Formulaciones de comprimidos que contienen sales de 8- [( 1- ( 3,5- bis- (trifluorometil) fenil) -etoxi ) - metil) -8- fenil -1, 7- diaza- spiro [ 4,5] decan -2- ona y comprimidos elaborados a partir de estas - Google Patents

Formulaciones de comprimidos que contienen sales de 8- [( 1- ( 3,5- bis- (trifluorometil) fenil) -etoxi ) - metil) -8- fenil -1, 7- diaza- spiro [ 4,5] decan -2- ona y comprimidos elaborados a partir de estas

Info

Publication number
AR065802A1
AR065802A1 ARP080101153A ARP080101153A AR065802A1 AR 065802 A1 AR065802 A1 AR 065802A1 AR P080101153 A ARP080101153 A AR P080101153A AR P080101153 A ARP080101153 A AR P080101153A AR 065802 A1 AR065802 A1 AR 065802A1
Authority
AR
Argentina
Prior art keywords
phenyl
disintegrant
decan
tablet
bis
Prior art date
Application number
ARP080101153A
Other languages
English (en)
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39541515&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR065802(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of AR065802A1 publication Critical patent/AR065802A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Formulaciones farmacéuticas que contienen una sal de (5S,8S)-8-[{(1R)-1-(3,5-Bis-(trifluorometil)fenil)-etoxi}-metil]-8-fenil-1,7-diazaspiro[4,.5]decan-2-ona, de formula (1), que son adecuadas para elaborar una forma galénica en comprimido, así comolas formas galénicas en comprimido. Métodos de tratamiento para los que se utilizan dichas formas galénicas. Reivindicacion 1: Una formulacion farmacéutica en polvo, que comprende: (a) un granulado que comprende, al menos, una sal cristalina de laformula 1, celulosa microcristalina intragranular, monohidrato de lactosa, un desintegrante primario, y un aglutinante; y combinados en seco con esta, (b) celulosa microcristalina extragranular, un segundo desintegrante y estearato de magnesio,donde la formulacion proporciona, después de la compresion en una prensa de comprimidos, un comprimido prensado con una dureza de, al menos, 10 kp. Reivindicacion 2: La formulacion de la reivindicacion 1, donde dicho primer desintegrante y dichosegundo desintegrante son sodio croscarmeloso. Reivindicacion 3: La formulacion de la reivindicacion 1, donde dicho aglutinante se selecciona de entre povidona K30, almidon pregelatinizado e hipromelosa 2910, 6 cps.
ARP080101153A 2007-03-22 2008-03-19 Formulaciones de comprimidos que contienen sales de 8- [( 1- ( 3,5- bis- (trifluorometil) fenil) -etoxi ) - metil) -8- fenil -1, 7- diaza- spiro [ 4,5] decan -2- ona y comprimidos elaborados a partir de estas AR065802A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US91950107P 2007-03-22 2007-03-22

Publications (1)

Publication Number Publication Date
AR065802A1 true AR065802A1 (es) 2009-07-01

Family

ID=39541515

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080101153A AR065802A1 (es) 2007-03-22 2008-03-19 Formulaciones de comprimidos que contienen sales de 8- [( 1- ( 3,5- bis- (trifluorometil) fenil) -etoxi ) - metil) -8- fenil -1, 7- diaza- spiro [ 4,5] decan -2- ona y comprimidos elaborados a partir de estas

Country Status (11)

Country Link
US (3) US8361500B2 (es)
EP (1) EP2136793B1 (es)
JP (3) JP5442459B2 (es)
AR (1) AR065802A1 (es)
CA (1) CA2681465C (es)
CL (1) CL2008000819A1 (es)
ES (1) ES2406934T3 (es)
MX (1) MX2009010210A (es)
PE (1) PE20081891A1 (es)
TW (1) TWI350185B (es)
WO (1) WO2008118331A2 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20030762A1 (es) 2001-12-18 2003-09-05 Schering Corp Compuestos heterociclicos como antagonistas nk1
PT2004646T (pt) 2006-04-05 2016-07-14 Opko Health Inc Sais cloridrato de 8-[{1-(3,5-bis-(trifluorometil)fenil)- etoxi} -metil]-8-fenil-1,7-diazaespiro[4.5]decan-2-ona e processo para a sua preparação
EP2004148B1 (en) 2006-04-05 2015-07-15 OPKO Health, Inc. Pharmaceutical formulations comprising salts of (5S,8S)-8-[{(1 R)-1-(3,5-Bis-trifluoromethyl)phenyl]- ethoxy}-methyl]-8-phenyl-1 ,7-diazaspiro[4.5]decan-2-one and their medical use
CA2653384C (en) 2006-06-30 2017-03-14 Iceutica Pty Ltd Methods for the preparation of biologically active compounds in nanoparticulate form
AR066191A1 (es) 2007-03-22 2009-08-05 Schering Corp Proceso e intermediarios para la sintesis de compuestos 8- [ ( 1- (3,5- bis- ( trifluorometil) fenil) - etoxi ) - metil]- 8 fenil - 1,7- diaza - espiro (4, 5) decan -2 ona
PE20081891A1 (es) 2007-03-22 2008-12-27 Opko Health Inc Formulaciones de comprimidos que contienen sales de 8-[{1-(3,5-bis-(trifluorometil)fenil)-etoxi}-metil]-8-fenil-1,7-diaza-spiro[4.5]decan-2-ona y comprimidos elaborados a partir de estas
RU2010139315A (ru) 2008-03-17 2012-04-27 Биал - Портела Энд Ка., С.А. (Pt) Кристаллические формы 5-[3-(2,5-дихлор-4,6-диметил-1-окси-пиридин-3-ил)[1,2,4]оксадиазол-5-ил]-3-нитробензол-1,2-диола
CN104496988B (zh) 2008-09-05 2017-04-12 欧科生医股份有限公司 用于合成8‑[{1‑(3,5‑双‑(三氟甲基)苯基)‑乙氧基}‑甲基]‑8‑苯基‑1,7‑二氮杂‑螺[4.5]癸‑2‑酮化合物的方法和中间体
EP2413912B1 (en) 2009-04-01 2019-03-13 Bial-Portela & CA, S.A. Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making thereof
DK2413913T3 (da) * 2009-04-01 2022-06-13 Bial Portela & Ca Sa Farmaceutiske formuleringer omfattende nitrocatecholderivater og fremgangsmåder til fremstilling deraf
PH12015501811A1 (en) * 2009-04-24 2019-03-25 Iceutica Pty Ltd Production of encapsulated nanoparticles at high volume fractions
WO2010121324A1 (en) * 2009-04-24 2010-10-28 Iceutica Pty Ltd A novel formulation of metaxalone
UA110773C2 (uk) * 2009-04-24 2016-02-25 Айсьютіка Пті Лтд Спосіб одержання порошків, що містять нано- і мікрочастинки
MA33292B1 (fr) * 2009-04-24 2012-05-02 Iceutica Pty Ltd Production de nanoparticules encapsulees a des fins commerciales
CN102438593A (zh) 2009-04-24 2012-05-02 伊休蒂卡有限公司 高体积分数的包封纳米颗粒的制备
AU2010239081C1 (en) 2009-04-24 2014-11-06 Iceutica Pty Ltd A novel formulation of indomethacin
JO3635B1 (ar) 2009-05-18 2020-08-27 Millennium Pharm Inc مركبات صيدلانية صلبة وطرق لانتاجها
EP2464230B1 (en) * 2009-08-14 2016-10-05 OPKO Health, Inc. Intravenous formulations of rolapitant
GB2475701B (en) * 2009-11-26 2011-10-19 Michael Hilary Burke A process for the preparation of an orally administered anthelmintic unit dose tablet
US20130303519A1 (en) 2012-03-20 2013-11-14 Millennium Pharmaceuticals, Inc. Methods of treating cancer using aurora kinase inhibitors
US9452107B2 (en) * 2012-04-16 2016-09-27 New Jersey Institute Of Technology Systems and methods for superdisintegrant-based composite particles for dispersion and dissolution of agents
CA2907726A1 (en) 2013-03-22 2014-09-25 Millennium Pharmaceuticals, Inc. Combination of catalytic mtorc1/2 inhibitors and selective inhibitors of aurora a kinase
US9526734B2 (en) 2014-06-09 2016-12-27 Iceutica Pty Ltd. Formulation of meloxicam
CN106866669A (zh) * 2017-04-19 2017-06-20 成都百特万合医药科技有限公司 一种合成罗拉吡坦中间体的方法
MX2022000816A (es) * 2019-07-19 2022-05-13 The Global Alliance For Tb Drug Dev Inc Composiciones de pretomanida.
WO2023080910A1 (en) * 2020-11-18 2023-05-11 Fb-Hrs, Llc Compositions containing dofetilide and mexiletine and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1090935C (zh) 1995-02-28 2002-09-18 阿温蒂斯药物公司 哌啶子基烷醇化合物的药物组合物
SA99191255B1 (ar) * 1998-11-30 2006-11-25 جي دي سيرل اند كو مركبات سيليكوكسيب celecoxib
US6499984B1 (en) 2000-05-22 2002-12-31 Warner-Lambert Company Continuous production of pharmaceutical granulation
WO2002024166A1 (fr) * 2000-09-22 2002-03-28 Sumitomo Pharmaceuticals Company, Limited Preparations orales dotees de bonnes caracteristiques de desagregation
PE20030762A1 (es) 2001-12-18 2003-09-05 Schering Corp Compuestos heterociclicos como antagonistas nk1
PT1635830E (pt) * 2002-09-17 2008-12-31 Wyeth Corp Formulação granulada do éster de rapamicina cci-779
AP2174A (en) 2003-10-03 2010-11-20 Pfizer Imidazopyridine substituted tropane derivatives with CCR5 receptor antagonist activity for the treatment of HIV and inflamation.
AU2004308935A1 (en) * 2003-12-22 2005-07-14 Schering Corporation Pharmaceutical compositions
JP2007532511A (ja) * 2004-04-09 2007-11-15 スミスクライン ビーチャム コーポレーション 低用量医薬品
US7354922B2 (en) 2004-12-14 2008-04-08 Schering Corporation Bridged ring NK1 antagonists
EP2004148B1 (en) * 2006-04-05 2015-07-15 OPKO Health, Inc. Pharmaceutical formulations comprising salts of (5S,8S)-8-[{(1 R)-1-(3,5-Bis-trifluoromethyl)phenyl]- ethoxy}-methyl]-8-phenyl-1 ,7-diazaspiro[4.5]decan-2-one and their medical use
PT2004646T (pt) 2006-04-05 2016-07-14 Opko Health Inc Sais cloridrato de 8-[{1-(3,5-bis-(trifluorometil)fenil)- etoxi} -metil]-8-fenil-1,7-diazaespiro[4.5]decan-2-ona e processo para a sua preparação
PE20081891A1 (es) 2007-03-22 2008-12-27 Opko Health Inc Formulaciones de comprimidos que contienen sales de 8-[{1-(3,5-bis-(trifluorometil)fenil)-etoxi}-metil]-8-fenil-1,7-diaza-spiro[4.5]decan-2-ona y comprimidos elaborados a partir de estas

Also Published As

Publication number Publication date
US20150283121A1 (en) 2015-10-08
JP2015108023A (ja) 2015-06-11
PE20081891A1 (es) 2008-12-27
WO2008118331A2 (en) 2008-10-02
ES2406934T3 (es) 2013-06-10
US20130122088A1 (en) 2013-05-16
JP5763134B2 (ja) 2015-08-12
EP2136793B1 (en) 2013-02-20
WO2008118331A3 (en) 2009-04-23
US8361500B2 (en) 2013-01-29
EP2136793A2 (en) 2009-12-30
JP2010522173A (ja) 2010-07-01
TW200902087A (en) 2009-01-16
JP2013216694A (ja) 2013-10-24
CA2681465A1 (en) 2008-10-02
CL2008000819A1 (es) 2008-09-26
US20100104637A1 (en) 2010-04-29
JP5442459B2 (ja) 2014-03-12
CA2681465C (en) 2015-12-15
JP6041919B2 (ja) 2016-12-14
MX2009010210A (es) 2009-10-19
TWI350185B (en) 2011-10-11

Similar Documents

Publication Publication Date Title
AR065802A1 (es) Formulaciones de comprimidos que contienen sales de 8- [( 1- ( 3,5- bis- (trifluorometil) fenil) -etoxi ) - metil) -8- fenil -1, 7- diaza- spiro [ 4,5] decan -2- ona y comprimidos elaborados a partir de estas
RU2465263C2 (ru) Фармацевтическая комбинация, включающая 3-(3-диметиламино-1-этил-2-метилпропил)фенол и нестероидный противовоспалительный препарат
US9095519B2 (en) Dosage form containing two or more active pharmaceutical ingredients in different physical forms
AR065096A1 (es) Preparacion solida
FI2508188T3 (fi) Dapagliflotsiinipropyleeniglykolihydraattia sisältäviä farmaseuttisia formulaatioita
US20090186086A1 (en) Solid multilayer oral dosage forms
US20120100221A1 (en) Pharmaceutical compositions containing a combination of an antihistamine and a decongestant
JP2010518028A5 (es)
NZ734446A (en) Pharmaceutical formulations of bruton’s tyrosine kinase inhibtor
RU2006146971A (ru) Таблетка с покрытием
PE20080054A1 (es) Formulaciones farmaceuticas de sales de 8-[1-(3,5-bis-(triflourometil)fenil)-etoximetil]-8-fenil-1,7-diaza-espiro[4,5]decan-2-ona
JP2008501025A5 (es)
RU2011127989A (ru) Таблетки на основе улипристала ацетата
NO20084065L (no) Hurtig frigivelses paracetamol tabletter
AR044142A1 (es) Formulacion farmaceutica de la sal sodica del telmisartan
MX2015003866A (es) Una formulacion farmaceutica oral solida que contiene ticagrelor.
JP2012167125A5 (es)
HRP20131088T1 (hr) Äśvrsti farmaceutski pripravci s fiksnom dozom koji sadrže irbesartan i amlodipin, njihova priprava i terapijska primjena
CZ2013783A3 (cs) Stabilní farmaceutická kompozice obsahující amlodipin a valsartan
WO2009084003A1 (en) Pharmaceutical compositions of amlodipine and valsartan
WO2012173581A4 (en) Thiocolchicoside, etodolac and famotidine combinations
Majeed et al. Formulation and evaluation of bilayer matrix tablets of amoxicillin and esomeprazole as an oral modified release dosage form for treatment of peptic ulcer
US20150231085A1 (en) Pharmaceutical composite capsule formulation comprising irbesartan and hmg-coa reductase inhibitor
Mahapatra et al. Development of modified-release tablets of zolpidem tartrate by biphasic quick/slow delivery system
RU2014145845A (ru) Таблетка с замедленным высвобождением, содержащая леводропропизин и способ ее изготовлеия

Legal Events

Date Code Title Description
FC Refusal